# Non-Small Cell Lung Cancer
Itraconazole has important early clinical relevance in **non-small cell lung cancer**, especially as an adjunct to pemetrexed.
### Overview
The main NSCLC signal is from phase II combination data, which supports the anti-angiogenic and adjunctive-treatment logic of the drug.
### Key human data
* A phase II trial used itraconazole **200 mg daily** with pemetrexed in advanced NSCLC
* Progression-free survival was **5.5 months** compared with **2.8 months** in the pemetrexed-only group
### Practical interpretation
This is one of the clearer examples of itraconazole being studied as a genuine adjunct rather than just a mechanistic curiosity.
### References
Repurposing itraconazole for the treatment of cancer\
{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}
{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}
---
# Agent Instructions: Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter:
```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology/itraconazole-evidence-by-cancer-type/non-small-cell-lung-cancer.md?ask=
```
The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.